$PPBT these past few bio buyouts have been phaseI and phase II, despite what crooked has said in the past, these have all been billion dollar deals without seeing every last result. We know Issac has mono results. I’m making the assumption he has early comb therapy numbers as well the early sites they rushed thru since sept 2020. Now we have 4/6 already running. IMO, purple would be the earliest of buyouts. With numbers as promising as they are, evaluation would be commiserate with the future sales. Pharma knows the longer they wait, the more pricey this will be. With a drug like this and no value to value, this can break the bank. Pharm knows this. They can save a boat load jumping in early. Sounds like a skilled negotiator like Gagnon will be needed. Thank gd we have him.